ArticleScientific reports2024
StructmRNA a BERT based model with dual level and conditional masking for mRNA representation.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- annATAC: automatic cell type annotation for scATAC-seq data based on language model.BMC biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In this study, we introduce StructmRNA, a new BERT-based model that was designed for the detailed analysis of mRNA sequences and structures. The success of DNABERT in understanding the intricate language of non-coding DNA with bidirectional encoder representations is extended to mRNA with StructmRNA. This new model uses a special dual-level masking technique that covers both sequence and structure, along with conditional masking. This enables StructmRNA to adeptly generate meaningful embeddings for mRNA sequences, even in the absence of explicit structural data, by capitalizing on the intricate sequence-structure correlations learned during extensive pre-training on vast datasets. Compared to well-known models like those in the Stanford OpenVaccine project, StructmRNA performs better in important tasks such as predicting RNA degradation. Thus, StructmRNA can inform better RNA-based treatments by predicting the secondary structures and biological functions of unseen mRNA sequences. The proficiency of this model is further confirmed by rigorous evaluations, revealing its unprecedented ability to generalize across various organisms and conditions, thereby marking a significant advance in the predictive analysis of mRNA for therapeutic design. With this work, we aim to set a new standard for mRNA analysis, contributing to the broader field of genomics and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.